Home › Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology
 

Keywords :   


Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology

2014-12-11 14:21:39| Biotech - Topix.net

Advaxis, Inc. , a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its Lm -LLO immunotherapy technology is featured in an article in the December 2014 issue of Nature Biotechnology . Entitled " Listeria vaccines join the checkpoint frenzy," the article explores the potential of the Listeria bacterium as a vector to enhance an anti-tumor response given its ability to induce powerful innate and adaptive immune responses.

Tags: featured nature biotechnology immunotherapy

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Atlantic Tropical Weather Outlook
29.06Eastern North Pacific Tropical Weather Outlook
28.06What we learned from IT expert at Post Office inquiry
28.06M&S to launch clothing repairs service
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
More »